Document Type

Article

Publication Date

2019

Keywords

Ganglioside GM1, monosialotetrahexosylganglioside, stroke

Abstract

Ganglioside GM1 is a member of the ganglioside family which has been used in many countries and is thought of as a promising alternative treatment for preventing several neurological diseases, including cerebral ischemic injury. The therapeutic effects of GM1 have been proved both in neonates and in adults following ischemic brain damage; however, its clinical efficacy in patients with ischemic stroke is still uncertain. This review examines the recent knowledge of the neuroprotective properties of GM1 in ischemic stroke, collected in the past two decades. We conclude that GM1 may have potential for stroke treatment, although we need to be cautious in respect of its complications.

Digital Object Identifier (DOI)

https://doi.org/10.1177/0963689718822782

Rights Information

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

Citation / Publisher Attribution

Cell Transplantation, v. 28, issue 6, p. 657-661

Was this content written or created while at USF?

Yes

Included in

Neurosurgery Commons

Share

COinS